## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($117.97)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Gifford Fong Associates Sells 25,000 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251201T095233 | Somewhat-Bullish | Relevance: 99%
- Gifford Fong Associates significantly reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by selling 25,000 shares in the second quarter, retaining 9,000 shares valued at approximately $998,000. This follows recent insider selling by the CFO and CEO. Despite the share sales, Gilead Sciences has reported strong quarterly earnings, beating analyst estimates, and provided positive FY2025 guidance, with analysts largely maintaining a "Moderate Buy" rating.

**2. Norges Bank Purchases New Stake in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251129T134221 | Bullish | Relevance: 99%
- Norges Bank acquired a new stake of 19,394,502 shares in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, valued at approximately $2.15 billion, representing about 1.56% ownership. This move comes amid insider selling from CFO Andrew Dickinson and Johanna Mercier, while the company reported strong Q2 earnings, beating analyst estimates, and issued positive FY2025 guidance.

**3. |Railway Pension Investments Ltd Reduces Holdings in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251201T163638 | Somewhat-Bullish | Relevance: 99%
-  |Railway Pension Investments Ltd trimmed its stake in Gilead Sciences by 4.1% in Q2, making it its second-largest holding. Despite this reduction, several other major institutions increased their positions, while insiders have been selling shares. Gilead reported strong quarterly earnings, issued positive FY2025 EPS guidance, and declared a quarterly dividend.

**4. WealthTrust Axiom LLC Decreases Stock Position in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251129T134221 | Somewhat-Bullish | Relevance: 98%
- WealthTrust Axiom LLC reduced its stake in Gilead Sciences by 12.3% in Q2 2025, selling 6,258 shares but still holding 44,574 shares worth approximately $4.94 million. Despite this reduction, many other institutional investors increased their positions, including Vanguard, Geode Capital Management, Price T Rowe Associates Inc. MD, UBS AM, and Nuveen LLC. The article also details Gilead's strong Q3 earnings, FY2025 guidance, dividend announcement, and recent insider stock sales.

**5. Gilead Sciences (GILD) Stock Outlook: Mizuho Lifts Target Amid Stronger Biktarvy Timeline**
- Source: Insider Monkey | 20251129T130900 | Neutral | Relevance: 98%
- Mizuho increased its price target for Gilead Sciences (GILD) from $131 to $140, maintaining an Outperform rating due to a stronger Biktarvy timeline, with market exclusivity now expected until 2036. This positive outlook is tempered by the failure of Gilead's Trodelvy in a Phase 3 trial for metastatic breast cancer, though potential in the pre-exposure prophylaxis market for Yeztugo is noted.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $150 | $145 | +3% |
| 2025-11-13 | Needham | $140 | $133 | +5% |
| 2025-11-13 | Scotiabank | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-11-13 | Needham | main | Buy |
| 2025-11-13 | Scotiabank | init | Sector Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($10.00M) |
| Sells | 14 ($7.11M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.0% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $7.1M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.21 indicates undervaluation relative to growth. Forward P/E 14.3x stretched relative to 7% growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $150.6B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.21 |
| Forward P/E | 14.3 |
| Current P/E | 15.2 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.5% to -3.5% (-3.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.5pp (needs >3.0% for momentum thesis). Underperforming sector by 4.9pp, stock-specific weakness. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.54% (CS: 9) | Weak |
| RSI_14 | 52.4 | Neutral |
| MACD Histogram | -0.17 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.038x | Above |
| vs SMA200 | 1.104x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $124.33
- **Stop Loss:** $117.97 (5.1% risk)
- **Target:** $130.69 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 117
- **Position Value:** $14,546.61
- **Portfolio %:** 14.55%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*